RegulatoryJun 18, 2026, 08:14 AM
Silo Pharma Regains Nasdaq Minimum Bid Price Compliance
AI Summary
Silo Pharma announced it has regained compliance with The Nasdaq Stock Market LLC's minimum closing bid price requirement as of June 17, 2026, and the matter is now closed. CEO Eric Weisblum thanked investors and expressed confidence in advancing the first-in-human clinical trial for SPC-15, targeting PTSD, and progressing its AI agents platform, QwikAgents. The company focuses on novel therapeutics for underserved conditions including stress-induced psychiatric disorders, chronic pain, and CNS diseases.
Key Highlights
- Silo Pharma regained compliance with Nasdaq's minimum closing bid price requirement.
- The compliance was confirmed by The Nasdaq Stock Market LLC on June 17, 2026.
- The matter regarding the bid price requirement is now closed.
- Silo's common stock continues to trade on the Nasdaq Capital Market.
- CEO Eric Weisblum expressed confidence in advancing SPC-15 for PTSD to clinical trials.
- The company is also progressing its AI agents platform, QwikAgents.
Price Impact
More from SILO